HJLI - Hancock Jaffe Laboratories, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Hancock Jaffe Laboratories, Inc.

70 Doppler
Irvine, CA 92618
United States
949-261-2900
http://www.hancockjaffe.com

SectorHealthcare
IndustryMedical Devices
Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Mr. Robert A. BermanCEO & Director398.67kN/A1963
Mr. Robert A. RankinCFO, Sec. & Treasurer238.45kN/A1953
Dr. Benedict Broennimann M.D.Chief Medical Officer of Outside of United States240kN/A1957
Dr. Marc H. GlickmanSr. VP & Chief Medical Officer362.64kN/A1949
Mr. Warren HancockCo-founderN/AN/AN/A
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Hancock Jaffe Laboratories, Inc., a development stage company, develops and sells biological based tissue solutions for patients with cardiovascular disease, and peripheral arterial and venous disease in the United States and Europe. The company develops and manufactures bioprosthetic implantable devices for cardiovascular diseases, including the VenoValve, a porcine based device to be surgically implanted in the deep venous system of the leg to treat chronic venous insufficiency; the CoreoGraft, a bovine based off the shelf conduit to be used to revascularize the heart during coronary artery bypass graft surgeries; and the Bioprosthetic Heart Valve, a porcine based heart valve designed to function like a native heart valve used for pediatric heart valve recipients. It also provides research, development, and contract manufacturing services. Hancock Jaffe Laboratories, Inc. was founded in 1987 and is based in Irvine, California.

Corporate Governance

Hancock Jaffe Laboratories, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.